Skip to main content

Table 1 Demographic and clinical characteristics of the BMD <70 % of YAM and BMD ≥70 % of YAM groups

From: Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics

  BMD <70 % of YAM BMD ≥70 % of YAM p value
Age 65.0 (58.0–69.0) 58.0 (53.0–66.0) 0.0044*
Proportion female 93.0 % 77.9 % 0.0079*
Disease duration (year) 15.0 (8.0–20.0) 8.0 (4.0–15.0) 0.0004*
BMI 21.4 ± 2.8 23.6 ± 3.3 <0.0001*
Rate of rheumatoid vasculitis 1.8 % 1.6 % 0.67
Proportion taking methylprednisolone 45.6 % 40.3 % 0.52
Dose of methylprednisolone (mg) 2.0 (1.0–3.5) 3.3 (2.0–6.0) 0.65
CRP (mg/dL) 0.09 (0.03–0.31) 0.08 (0.03–0.37) 0.89
DAS28-CRP 2.63 (1.88–3.38) 2.50 (1.70–3.30) 0.49
CDAI 6.70 (2.90–14.90) 5.80 (2.60–12.95) 0.54
SDAI 6.95 (3.05–14.10) 6.30 (2.74–12.94) 0.58
MHAQ score 9.00 (1.00–14.00) 4.00 (0.00–8.00) 0.002*
History of proximal femoral fracture 2/57 0/129 0.087
History of thoracic or lumbar vertebral fracture 17/57 9/129 <0.001*
Duration of biologics therapy 4.2 ± 2.6 3.6 ± 2.3 0.166
  1. BMD bone mineral density, YAM young adult mean, BMI body mass index, CRP serum C-reactive protein concentration, DAS28-CRP Disease Activity Score-28-CRP, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, MHAQ Modified Health Assessment Questionnaire